Safer antibody therapy developed for pregnant women
Adding a small protein reduces fetal risk from antibody drugs
1Risks of antibody drugs in pregnancy
Antibody-based drugs are used to treat cancer and autoimmune diseases. However, they can have adverse effects on the fetus during pregnancy. This risk poses a significant challenge for treating serious conditions that require intervention during gestation. Scientists have developed a novel approach to address this issue.
2Protein conjugation technology
Researchers successfully reduced fetal harm by attaching a small protein to antibody drugs. This method limits the drug's ability to cross the placental barrier. The study, published in Science Immunology, is based on 2026 preclinical trials. The approach maintains therapeutic efficacy while minimizing off-target effects.
3Clinical application potential
The method proved successful in mouse models, with no observed negative impact on fetal development in treated pregnant mice. These findings suggest potential similar outcomes in humans. The technology could revolutionize treatment of autoimmune diseases like lupus during pregnancy, where current options are limited.
4Limitations of current treatments
Many drugs are restricted during pregnancy due to fetal safety concerns, severely limiting treatment options for expectant mothers. This new approach paves the way for therapies that protect maternal health without harming the baby. The $2.8 billion pregnancy-safe drug market could expand significantly with this technology.
5Scientific mechanism
The added protein modifies the antibody's Fc receptor binding properties, preventing placental transfer. This preserves the drug's therapeutic action while eliminating fetal exposure. The technology is adaptable to various antibody treatments, offering broad application potential across different medical conditions.
6Industry implications
The discovery enables pharmaceutical companies to develop new treatments for pregnant patients. Major drug manufacturers are already in talks with the research team about patent rights. The method could accelerate development timelines by allowing modification of already-approved antibody therapies.
7Regulatory considerations
FDA and EMA have formed special working groups to evaluate this technology. Since it modifies existing approved drugs rather than creating new compounds, it may face fewer regulatory hurdles. This could significantly shorten the path to clinical availability for pregnant patients in need.
8Future research directions
The team is now testing different protein variants to identify the most effective combination. Human clinical trials are planned for 2027. If successful, this technology could extend beyond pregnancy to pediatric applications. It represents a major advancement in personalized medicine approaches for vulnerable populations.
Original article: Nature — Hamileler için daha güvenli antikor tedavisi geliştirildi